Zook, P., Pathak, H. B., Belinsky, M. G., Gersz, L., Devarajan, K., Zhou, Y., . . . Rink, L. (2016). Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor. Clin Cancer Res.

Zook, Phillip, Harsh B. Pathak, Martin G. Belinsky, Lawrence Gersz, Karthik Devarajan, Yan Zhou, Andrew K. Godwin, Margaret von Mehren, and Lori Rink. "Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor." Clin Cancer Res 2016.

Zook, Phillip, et al. "Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor." Clin Cancer Res 2016.